DrugandAlcoholDependence105 (2009) 9–15
ContentslistsavailableatScienceDirect
Drug and Alcohol Dependence
journal homepage: www.elsevier.com/locate/drugalcdep
Mortality among clients of a state-wide opioid pharmacotherapy program over
(cid:2)
20 years: Risk factors and lives saved
LouisaDegenhardta,∗,DeborahRandalla,WayneHallb,MatthewLawc,TonyButlerd,LucyBurnsa
aNationalDrugandAlcoholResearchCentre,UniversityofNSW,Sydney,NSW2052,Australia
bSchoolofPopulationHealth,UniversityofQueensland,Herston,QLD4008,Australia
cNationalCentreinHIVEpidemiologyandClinicalResearch,TheUniversityofNewSouthWales,376VictoriaStreet,Darlinghurst,NSW2010,Australia
dNationalDrugResearchInstitute,CurtinUniversityofTechnology,Level2,10SelbyStreet,ShentonPark,WA6008,Australia
a r t i c l e i n f o a b s t r a c t
Articlehistory: Background:Thesmallsizeofpreviousstudiesofmortalityinopioiddependentpeoplehasprevented
Received24March2009 anassessmentoftheextenttowhichelevatedmortalityrisksareconsistentacrosstime,clinicaland/or
Receivedinrevisedform11May2009 patientgroups.Thecurrentstudyexaminesreductionsinmortalityrelatedtotreatmentinanentire
Accepted14May2009
treatmentpopulation.
Available online 15 July 2009
Methods:DatafromtheNewSouthWales(NSW)PharmaceuticalDrugsofAddictionSystem,recording
every“authoritytodispense”methadoneorbuprenorphineasopioidreplacementtherapy,1985–2006,
Keywords:
waslinkedwithdatafromtheNationalDeathsIndex,arecordofalldeathsinAustralia.Crudemortality
Methadonemaintenance
ratesandstandardizedmortalityratioswerecalculatedaccordingtoage,sex,calendaryear,periodin-or
Buprenorphine
Mortality out-of-treatment,medicationtype,previoustreatmentexposureandcauseofdeath.
Causesofdeath Results:Mortalityamong42,676peopleenteringopioidpharmacotherapywaselevatedcomparedto
Datalinkage ageandsexpeers.Drugoverdoseandtraumawerethemajorcontributors.Mortalitywashigheroutof
Opioiddependence treatment,particularlyduringthefirstweeks,anditwaselevatedduringinductionontomethadonebut
notbuprenorphine.Mortalityduringtheseriskyperiodschangedacrosstimeandtreatmentepisodes.
Overall,mortalitywassimilarlyreduced(comparedtoout-of-treatment)whetherpatientswerereceiving
methadoneorbuprenorphine.Itwasestimatedthattheprogramproduceda29%reductioninmortality
acrosstheentirecohort.
Conclusions: Mortality among treatment-seeking opioid-dependent persons is dynamic across time,
patientandtreatmentvariables.Thecomparativereductioninmortalityduringbuprenorphineinduction
maybeoffsetbytheincreasedriskoflongerout-of-treatmenttimeperiods.Despiteperiodsofelevated
risk,thislarge-scaleprovisionofpharmacotherapyisestimatedtohaveresultedinsignificantreductions
inmortality.
© 2009 Elsevier Ireland Ltd. All rights reserved.
1. Introduction who inject drugs) (Degenhardt et al., 2004, 2006; Darke et al.,
2006).
Illicit opioid use, especially heroin injection, has caused sig- Themainstaysoftreatmentforopioiddependencearepharma-
nificant personal and public health problems in many countries cologicalmaintenanceonmethadoneandbuprenorphine,bothof
acrosstheglobe(UnitedNationsOfficeonDrugsandCrime,2008). whicharelistedontheWorldHealthOrganization’s(WHO)Model
Apart from the burden to users, their families and the broader List of Essential Medicines (World Health Organization, 2005) for
community, opioid dependence increases the risk of premature this indication. Methadone is an orally administered opioid ago-
mortality (Darke et al., 2006). This elevated risk is concentrated nist with a half-life of 24–36h. Multiple randomized controlled
acrossseveralcausesofdeath:accidentaldrugoverdose,suicide, trialshavefoundthatmethadonetreatmentdecreasesillicitopi-
trauma(e.g.motorvehicleaccidents,homicideorotherinjuries), oiduse,improvessocialfunctioning,decreasesoffendingbehaviors
and HIV (in countries where HIV is prevalent among people andimproveshealth(Wardetal.,1998;Matticketal.,2003).
Theneedforsuperviseddailydosingofmethadoneinadefined
treatment setting, and evidence of increase overdose death on
inductionintotreatmentpromptedthesearchforalternativephar-
(cid:2)
Additionalbackgroundmaterialsanddataanalysesareprovidedinsixappendi-
macologicaltreatmentoptions(Matticketal.,2001).Asapartial
ciesavailablewiththeonlineversionofthisarticleatdoi:xxxxxxxx.
∗ agonist,buprenorphineproduceslessdepressionofrespirationand
Correspondingauthor.Tel.:+61293850230;fax:+61293850222.
E-mailaddress:l.degenhardt@unsw.edu.au(L.Degenhardt). consciousnessthanmethadone,therebyreducingtheoverdoserisk.
0376-8716/$–seefrontmatter© 2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.drugalcdep.2009.05.021
10 L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15
Buprenorphineislongeractingthanmethadone,allowingforless insomecasesfromcoronialfiles.Fordeathsoccurringbetween1985and1996,
thandailydosing. causesofdeathwerecodedaccordingtoICD-9(WorldHealthOrganization,1977).
Opioid pharmacotherapy is not without its own risks (Ward Fordeathsoccurringbetween1997and2006,causesofdeathwerecodedusingICD-
10codes(WorldHealthOrganization,1993).Onlyunderlyingcauseswerecodedin
et al., 1998), nor does it completely remove the excess mortal-
the1985–1996period,definedasthe“diseaseorinjurywhichinitiatedthetrain
ityrisksthatopioiddependentpersonsareknowntoface(Darke ofmorbideventsleadingdirectlytodeath,orthecircumstancesoftheaccidentor
et al., 2006). Work has shown, for example, high mortality dur- violencewhichproducedthefatalinjury”(AustralianBureauofStatistics,2007);
ing the period of induction onto methadone (Caplehorn, 1998; butupto19contributingcausesofdeathwerecodedfrom1997onwards.Only
underlyingcauseswereexaminedinthisstudy(apartfromopioiddeathsfrom1997
Buster et al., 2002). More recent work has found that induc-
onwardsthatwerecross-classifiedwithparticularsubstancecodes).Thesewere
tionontomethadone,andcessation,carryelevatedmortalityrisks
groupedintorelatedconditionsaccordingtoICDcodesbasedonpublishedexpert
(CaplehornandDrummer,1999;Busteretal.,2002;Brugaletal., consensusstatementsorhealthdepartmentprotocols(seeWebAppendix1andalso
2005). (Randalletal.,2009)forgroupingsandsourcesfordefinitions).
Thesmallsamplesizeofthesestudieshaspreventedanassess-
2.2. Datalinkage
ment of the extent to which these elevated risks are consistent
acrosstimeand/orpatientgroups.Fewexistingexaminationshave LinkagewithmortalitydatafromtheNationalDeathsIndexwasperformedby
hadsufficientpowertoexaminedifferencesinriskacrosstimeand staffattheAustralianInstituteofHealthandWelfare(AIHW)usinganin-house
patientlevelvariables.Further,thesestudieshavetypicallyfocused probabilisticrecordlinkageprogram.Variablesusedformatchingpurposesincluded
fullname,dateofbirth,sex,dateandstateoflastknowncontact.Alinkeddataset
ontreatmentgroupsratherthanacrossentiretreatmentprograms.
wasforwardedtotheinvestigatorsoncompletionoflinkage.
Noestimatesexistofthesizeofreductionsinmortalityrelatedto
treatmentforanentiretreatmentpopulationwhilealsoconsider- 2.3. Dataanalysis
ingotherimportantpredictorsofmortalityrisk.
Thecrudemortalityrates(CMRs)werecalculatedbysummingtheperson-
NewSouthWales(NSW)isthemostpopulousStateofAustralia,
yearscontributedbyeachparticipant,byage,sex,calendaryearandtreatment
with approximately six million residents. It has had an expand-
timeperiod,summingthenumbersofdeathsbythesamegroups,andcalculat-
ingandexpansiveopioidreplacementprograminplaceforalmost ingarateper1000person-years.Cruderateratios(RRs)werecalculatedbydividing
thirtyyears.Over40,000peoplehaveenteredtreatmentsince1985 onemortalityratebyanother.
(Burns et al., 2009). The size of this entire treatment population Indirectstandardizedmortalityratios(SMR)werecalculatedbydividingthe
observeddeathsinthecohortbytheexpecteddeathsbasedontheNSWpopulation
allows for an examination of important questions of clinical and
mortalityratesbyyear,sexandagegroup.
populationhealthinterest.Theaimsofthisstudywereto: Inthispaper,wehaveusedstratifiedanalysesofSMRs,whichallowedusto
comparegroups,whilesimultaneouslycomparingmortalityratesagainstthegen-
(i) Estimateoverallmortalityforallpersonsenteringopioidphar- eralpopulationofthesameageandsex.WealsousedPoissonregressiontoexamine
predictorsofmortalityduringtwotimeperiods:1985–2000(methadoneonlyused);
macotherapy between 1985 and 2006, by demographic and
and2001–2006(methadoneandbuprenorphine).Theresultsoftheseregressions
treatmentvariables;
havenotbeenincludedinthispaper;thefindingswereconsistentwiththeresults
(ii) Examine whether demographic or treatment variables were presentedinthebodyofthispaper(interestedreaderscanfinddetailsofthemod-
related to mortality levels during and following cessation of elsatWebAppendix2).Theobservedout-of-treatmentCMRwasappliedtothe
treatment; totalperson-yearsinthecohort,toprovideanestimateofthereductionsinmortal-
ityresultingfromthepharmacotherapyprogram.Thisassumesthatthemortality
(iii) Estimatemortalityrisk,accordingtospecificcausesofdeath,
reductionswereduetotreatment.Itisnonethelessaconservativeestimatebecause
duringtimewithintreatmentandfollowingcessationoftreat- itincludespersonswhodidnotdieduringtheirfirst(orsubsequent)treatment
ment; episode,henceunderestimatesthemortalityrateamonguntreatedopioiddepen-
(iv) Estimatethenumberoflivesthatmayhavebeensavedbythe dentpersons.Estimatednumbersofdeathsthatmighthavebeenavertedifthe
elevatedmortalityduringinductiondidnotexistweremadebyapplyingtheCMR
provisionofmethadoneandbuprenorphineinNSWoverthis
fortheremainderofthetreatmentperiodtothetotalperson-yearsduringinduc-
period;
tion(separatelyformethadoneandbuprenorphine).Analyseswereconductedin
(v) Considertheestimatedlivessavedfromimprovedclinicaldeliv- SASV9.1.3(SASInstituteInc.,Cary,NC,USA)andStataV9.2(StataCorpLP,College
eryofthesetreatments. Station,TX,USA).
2.4. Ethics
2. Methods
Ethicsapprovaltoconductthisstudywasreceivedfromallrelevantinstitutional
2.1. Sample
HumanResearchEthicsCommittees.
TheNSWPharmaceuticalDrugsofAddictionSystem(PHDAS)isadatabasethat
recordswhenanauthoritytodispensemethadoneorbuprenorphineinNSWasan 3. Results
opioidreplacementtherapytoaparticularpersonhasbeenapprovedbytheNSW
HealthDepartment.ThisstudyexaminedunitrecorddatafromthePHDASdatabase 3.1. Overallresults
onallpersonsenteringpharmacotherapytreatmentbetween1985and2006.
Exclusionsfromtheanalysisincluded:thosewhodidnotcommencetreatment;
thoseintemporaryprograms,suchinterstateclients;andbuprenorphineclinical Overthestudyperiod42,676clientsenteredtreatmentforatotal
trialparticipants,astheywerenotnecessarilygivenbuprenorphineduringthetrial. of425,998person-yearsoffollow-up(PY;median9.2years).The
Thereweremultipletreatmentepisodesformanyindividualsandthesewere medianepisodelengthwas198days,andparticipantsenteredinto
sometimes continuous. Previous research using the PHDAS data defined a new
anaverageof2.5treatmentepisodes.Furtherdetailsoftreatment
treatmentepisodeasonecoming7ormoredaysafterapreviousepisodehadfin-
retentionandre-entryarepresentedelsewhere(Burnsetal.,2009)
ished.Weadoptedthisdefinitionfollowingconsultationwithexpertsinclinical
researchandpractice(Degenhardtetal.,2005).Achangeinthemedicationpre- (seealsoWebAppendix3).
scribed(methadoneorbuprenorphine)wasconsideredacontinuousepisodeifthere Duringthefollow-upperiodtherewere3803deaths,withan
waslessthan7daysbetweenoneepisodeendandthenextepisodestart. overallCMRof8.9deathsper1000PY(95%CI:8.6–9.2;Table1).
Weadoptedthesamedefinitions–treatingthe6daysfollowingatreatment
CMRswerehigherinmalesthanfemales,andamongolderclients.
programaspartofthatprogram–whenallocatingdeathstoin-treatmentorout-
of-treatmenttimeperiods.Thereisapotentialbiasinthismethodologytoallocate ThepatternofSMRswasreversed,withagreaterexcessmortal-
deathstothetreatmentperiodthatactuallyoccurredafterleavingtreatment,but ityamongfemales,andagreaterexcessmortalityamongyounger
anysucherrorsbiasin-treatmentmortalityupwardsandout-of-treatmentmortal- clients.Mortalityrates(bothCMRsandSMRs)increasedovertime
itydownwards,resultinginconservativeestimatesofmortalityreductionduring
until1995–2000,andfellin2001–2006(Table1,Fig.1).
treatment.
The overall in-treatment SMR was 4.5 (95% CI 4.3, 4.8), com-
AlldeathsinAustraliaarecodedbyexpertclinicalcodersattheAustralianBureau
ofStatistics(ABS)onthebasisofinformationcontainedinthedeathcertificateand pared with an out-of-treatment SMR of 8.0 (95% CI 7.7, 8.3). The
L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15 11
Table1
Crudemortalityratesandstandardizedmortalityratiosaccordingtodemographicandtreatmentcharacteristicsamong42,676NSWopioidpharmacotherapytreatment
entrants,1985–2006.
Person-years Totaldeaths CMRper1000person-years 95%CI SMR 95%CI
Sex
Males 276095 2835 10.3 (9.9–10.7) 5.9 (5.7–6.1)
Females 149903 968 6.5 (6.1–6.9) 8.7 (8.1–9.2)
Agegroup
Lessthan20years 4735 30 6.3 (4.3–9.0) 12.1 (8.2–17.3)
20–29years 123143 932 7.6 (7.1–8.1) 8.7 (8.1–9.2)
30–39years 182329 1486 8.2 (7.7–8.6) 7.3 (7.0–7.7)
40+years 115791 1355 11.7 (11.1–12.3) 4.8 (4.6–5.1)
Calendaryear
1985–1989 21375 128 6.0 (5.0–7.1) 5.3 (4.4–6.3)
1990–1994 59666 506 8.5 (7.8–9.3) 7.1 (6.5–7.7)
1995–2000 136301 1525 11.2 (10.6–11.8) 8.6 (8.2–9.1)
2001–2006 208656 1644 7.9 (7.5–8.3) 6.2 (5.9–6.5)
Treatmentperiod
Firstweekintreatment 2178 86 39.5 (31.6–48.8) 35.4 (28.3–43.7)
Secondweekintreatment 2059 35 17.0 (11.8–23.6) 15.2 (10.6–21.2)
Remainderintreatment 198100 1102 5.6 (5.2–5.9) 4.1 (3.9–4.4)
Overallintreatment 202337 1223 6.0 (5.7–6.4) 4.5 (4.3–4.8)
Firstweekoutoftreatment 1666 29 17.4 (11.7–25.0) 15.3 (10.2–21.9)
Secondweekoutoftreatment 1591 32 20.1 (13.8–28.4) 17.6 (12.0–24.8)
Remainderoutoftreatment 220404 2519 11.4 (11.0–11.9) 7.9 (7.6–8.2)
Overalloutoftreatment 223661 2580 11.5 (11.1–12.0) 8.0 (7.7–8.3)
Medicationtype1
Receivingmethadone(1985–2000) 111538 648 5.8 (5.4–6.3) 4.6 (4.2–4.9)
Receivingmethadone(starting2001–2006) 12877 67 5.2 (4.0–6.6) 5.9 (4.5–7.4)
Receivingbuprenorphine(starting2001–2006) 4702 21 4.5 (2.8–6.8) 4.6 (2.8–7.0)
Firstmedicationtype(2001–2006)
Firstgivenmethadone(2001–2006) 21974 148 6.7 (5.7–7.9) 7.3 (6.2–8.6)
Firstgivenbuprenorphine(2001–2006) 12863 88 6.8 (5.5–8.4) 7.3 (5.8–9.0)
Total 425998 3803 8.9 (8.6–9.2) 6.4 (6.2–6.6)
Person-yearsdonotsumtototalasthisrefersonlytotimewhenreceivingmedications,and2001–2006figuresarejustforthosewhostartedtreatment2001onwards.
rateratiofortheout-of-treatmentCMRoverthein-treatmentCMR programfrom2001onwardsprescribedmethadoneandbuprenor-
showedsignificantlyincreasedmortalityout-of-treatment(RR1.9, phineinthe2001–2006periodrevealednosignificantdifferences
95%CI1.8–2.0,p<.001).Analysisofmortalitybytimeintreatment betweenthetwo(RR0.86,95%CI,0.50–1.42,p=.552),andtherewas
revealedthatthehighestmortalityriskwasduringthefirstweek, nodifferenceintheoverallSMRforthosefirstgivenmethadone(7.3,
with39.5deathsper1000yearsoffollowup(95%CI31.6,48.8),35.4 95%CI,6.2–8.6)incomparisonwiththosefirstgivebuprenorphine
timesthoseexpectedinthegeneralpopulationofthesameageand (7.3,95%CI,5.8–9.0)from2001to2006(Table1).
sex(95%CI28.3,43.7).Mortalitydroppedsharplyduringthesecond
treatmentweek,andwassignificantlylowerfortheremainderof 3.2. Treatmentinductionandcessation
thetreatmentperiodcomparedwiththesecondweek(5.6deaths
per1000person-years;95%CI5.2,5.9;rateratio(RR)0.33,95%CI Anumberofinteractionsexistedbetweentreatmentvariables
0.23–0.47,p<.001).Thelatterratewasstillfourtimeshigherthan andmortalityrisk.Theanalysiscomparinginductiononbuprenor-
thatinthegeneralpopulation(SMR4.1,95%CI3.9,4.4).Compar- phine and methadone was restricted to those who entered the
ison of in-treatment mortality levels among clients entering the program from 2001 onwards. Only one death was estimated to
Fig.1. Mortalitylevelsshownascrudemortalityratesper1000person-years(LeftPanel),andstandardizedmortalityratios(RightPanel)amongopioidpharmacotherapy
entrantsinNewSouthWales,1985–2006.
12 L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15
Fig.2. Interactionbetweenpriortreatmentandmortalityrisk(standardizedmortalityratios)accordingtotreatmentperiod.IntreatmentshownintheLeftPanel;outof
treatmentshownintheRightPanel.
have occurred during induction onto buprenorphine (CMR 2.5; Overall,theexcessmortalitywashighestforthoseoutoftreatment
95%CI:0.1–13.7);whereastheCMRforthosebeinginductedonto duringthe1995–2000period(Fig.3b).
methadone during 2001–2006 was 26.3 per 1000 PY (95% CI:
13.6–45.9)(RR0.09,95%CI0.002–0.63,p=.004).Themajorityof 3.3. Causesofdeath
inductiondeathsoccurredinthefirsttwoepisodes(oneoutofone
forbuprenorphineandsixoutofsevenformethadone).Nosignif- The lower average mortality observed during treatment was
icant differences in mortality risk existed immediately following found in a limited number of causes of death (Fig. 4a). The in-
cessation of buprenorphine versus methadone (RR 5.60, 95% CI: treatmentperiodwasassociatedwithlowermortalityfromopioid
0.63–264.75,p=.096)(WebAppendix4). andotherdrugoverdoses,anddeathsduetounintentionalinjury
Theexcessmortalityseeninthefirsttwoweeksoftreatment andsuicide(Fig.4a;seealsoWebAppendix5).HIVwasanuncom-
from1985to2006wasstronglyrelatedtopriortreatmentexpo- mon cause of death among the cohort, whether in or out of
sure:duringthefirsttreatmentepisode,theSMRduringthetwo treatment.
weekinductionperiodwas36.5(95%CI27.9,46.9),butitdecreased The interaction between treatment period and mortality
withsuccessiveepisodesto10.0(95%CI:3.7,21.7;Fig.2;seealso reflectedtheeffectsofspecificcausesofdeath.Duringthefirsttwo
Web Web Appendix 4) for a client entering their sixth (or later) weeksintreatment,mortalityduetoopioidsandotherdrugsand
treatment episode. This was a significant trend in the SMRs (RR unintentionalinjuryandsuicide,wereallatmuchhigherlevelsthan
0.73,95%CI:0.63,0.84,p<.001).Mortalityduringtreatmentover- thoseseenforanyotherperiod(inoroutoftreatment)(Fig.4b).The
all,however,wasunrelatedtopriortreatmentexposure(RR1.00, mortalityriskforthesesamecauseswasmarkedlyelevatedinthe
95%CI:0.96,1.04,p=.971;Fig.2a).Mortalityinthetwoweeksfol- firsttwoweeksoutoftreatment.
lowingcessationoftreatmentwasnodifferentdependingonthe Estimatedreductioninmortalityamongthiscohortassociated
number of prior treatment episodes (RR 0.93, 95% CI: 0.77, 1.12, withprovisionofopioidpharmacotherapy,1985–2006.
p=0.450;Fig.2b). Applyingtheoverallout-of-treatmentmortalityrate(11.5/1000
Mortalityriskduringtreatmentinductionwasassociatedwith PYs)tothetotalperson-years(425,998),itwasestimatedthat1111
calendar year (Fig. 3a) with the highest risk in the 1990–1994 additionaldeathswouldhaveoccurredduringthestudyperiodif
period,wheretheSMRwas52.9(95%CI:37.6,72.3).Theexcessmor- the treatment programme, as implemented, had not existed, an
talitydecreasedovertime,to16.5(95%CI:10.9,24.0)in2001–2006. increasein29%inoverallmortalityamongthisgroup.
Mortalityimmediatelyfollowingtreatmentcessationwascon- Estimateswerealsomadeofthenumberofdeathsthatmight
sistentlyelevatedacrosstimecomparedtothegeneralpopulation. havebeenavertediftheriskduringinduction(28.6/1000PYs)was
Fig.3. Interactionbetweencalendaryearandmortalityrisk(standardizedmortalityratios)accordingtotreatmentperiod.IntreatmentshownintheLeftPanel;outof
treatmentshownintheRightPanel.
L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15 13
Fig.4. Crudemortalityrates(per1000PY)duetospecificcausesaccordingtotreatmentperiod,1985–2005.OverallinandoutoftreatmentshownintheLeftPanel;First
twoweeksinandoutoftreatmentshownintheRightPanel.
thesameasthatduringtheremainderoftreatment(5.6/1000PYs). The causes of premature mortality were related to treatment
Withnoelevatedriskduringinduction,then121deathsobserved stage. The reductions in risk during treatment were greatest for
duringinductionmighthavebeenreducedto24,97fewerdeaths drug-induceddeaths,suicideandtraumaticdeaths.Thesearethe
acrosstheentirestudyperiod. mostcommoncausesofmortalityamongopioiddependentper-
sons (Darke et al., 2006); they are also fairly directly related to
patternsofdruguse,poormentalhealth,andhighriskbehaviors
4. Discussion
amongthosewithillicitdrugdependence.ThefactthatHIVmortal-
itywaslowamongthiscohortreflectsthesustainedlowprevalence
This is one of the largest and longest follow up studies of
ofHIVamongpeoplewhoinjectdrugsinAustralia(NationalCentre
personsreceivingopioidpharmacotherapyforillicitopioiddepen-
inHIVEpidemiologyandClinicalResearch,2007).This,inturn,is
dence. Data were examined on over 40,000 treatment entrants
linked to the early introduction of Needle and Syringe Programs
across a large State-based program for whom patterns of entry
(NSPs) and the expansion of the methadone program during the
anddeparturefromtreatmentweretracked.Timeintreatmentwas
mid1980swhenHIVwasfirstidentifiedinAustralia.Thefluctu-
associatedwithlowermortalitythantimeoutoftreatment,with
ationsinmortalityrateinandoutoftreatmentcouldalsoreflect
anoverallin-treatmentSMRof4.5(95%CI4.3,4.8),comparedtoan
changesintheheroinmarketinNSWduringtheperiod:mortal-
out-of-treatmentSMRof8.0(95%CI7.7,8.3)(RR1.9,95%CI1.8–2.0,
ityincreasedwhenheroinavailabilityincreasedduringthe1990s,
p<.001).
anddecreasedwhensupplycontractedafter2001(Degenhardtand
Thelargesamplesizeprovidedthenecessarystatisticalpower
Day,2004;Dayetal.,2006).
toconfirmpreviousobservationsthatinductionontomethadone
and the first fortnight following cessation of buprenorphine or
methadonetreatmentareparticularlyriskyperiods.Theseeleva- 4.1. Clinicalimplications
tionsinriskvariedovertimeandtreatmentexposures.Increased
prior treatment episodes were associated with reduced risk dur- Theobservedreductionsinmortalityduringtreatment,ifthey
inginduction.Thecalendarperiodwiththehighestmortalityrisk canbeentirelyattributedtotreatment,wereclinicallyimportant
during induction was 1990–1994 consistent with previous find- andofpopulationhealthsignificance.Atthepopulationlevel,the
ings (Caplehorn, 1998), with later reductions reflecting changes treatment program averted an additional 1111 deaths during the
inmethadonedosingpolicies.Post-treatmentmortalitywashigh- studyperiod.Thiswouldhaverepresenteda29%increaseinthe
est between 1995 and 2000 when heroin availability and purity observedmortalityrate.
were at their historically highest levels in NSW (Degenhardt Despitereductionsinthemortalityriskintheinductionperiod
and Day, 2004; Day et al., 2006). The decline in SMRs during formethadonefromthepeakin1990–1994,thefirsttwoweeksof
methadone induction with increasing treatment episodes may treatmentstillhasanunacceptablyelevatedmortalityrisk.Preven-
reflect selection effects, with those at highest risking dying ear- tive interventions are needed during induction onto methadone,
lier. particularly for first-time entrants to treatment. These need to
The continued elevated mortality risk during induction onto addressmentalhealthproblems,polydruguse,methadonedose,
methadonetotheendofthestudyperiodsuggeststhatdespitethe andlifestylemoregenerally.
adoptionofdosingpoliciestoreducerisk,moreconcertedefforts Althoughbuprenorphinedidnothavetheelevatedriskinthe
areneededtominimisetheserisks. inductionperiod,theoveralltreatmentmortalitylevelswerenot
Therearemorecomplexissuesforbuprenorphineclients.Previ- significantlydifferentforthoseinbuprenorphineandmethadone
ousanalysesfindingtheyarelesslikelytoberetainedintreatment treatment. In addition, those who entered buprenorphine were
thanmethadoneclients,andmorelikelytocycleinandoutoftreat- retained for shorter periods, and more likely to cycle in and out
mentandswitchbetweenmedications(Burnsetal.,2009).Thisisof of treatment (Burns et al., 2009), leading to more time spent in
concerngiventhattheperiodaftercessationwasequallyriskyfor periodswithahighermortalityrisk.Overall,thosewhostartedin
buprenorphineandmethadoneclients.Theconsequenceisthatany buprenorphinehadexactlythesamestandardizedmortalityratio
reductioninmortalityriskduringinductiontobuprenorphinemay asthosewhostartedinmethadone,from2001onwards.Interven-
beoffsetbyanincreasedmortalityduetolongerpost-treatment tions to increase retention in buprenorphine are also important
periods. There is a clear need to investigate options to increase giventhemortalityrisksfacedbythosewholeavetreatmentprior
retentioninbuprenorphinetreatment,whichmayincludereview tocompletion.
ofdosinglevelssinceinadequatelevelshavebeenassociatedwith Interventionsareneededtoreducetherisksofrelapsetodrug
poorerretentionintreatment. use and suicide risk at treatment cessation. This is particularly
14 L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15
trueamongthosewhohavecycledrepeatedlyinandoutoftreat- Conflictofinterest
ment.
L. Degenhardt has been provided with funding by Reckitt
Benckiser in the form of an untied educational grant to monitor
4.2. Limitations
theextentofinjectionofbuprenorphine-naloxoneinjectionafter
itsintroductioninAustraliaandtocomparethiswiththeinjection
In this study, we have compared mortality in- and out-of-
ofotherOSTforms.Thedesign,conductandinterpretationofthat
treatment.Itcouldbearguedthatmortalityintreatmentislower
study’sfindingsweretheworkofthestudyinvestigators;Reckitt
because the people who stay in treatment are more stable than
Benckiserhadnoroleinthese.
those who drop out. We doubt that this explains the difference,
forthreereasons.First,ourfindingsareconsistentwithevidence
Acknowledgements
fromrandomisedcontrolledtrialsfindingthatopioidsubstitution
treatmentreducesmortality(Matticketal.,2003).Second,inour
WewouldliketoacknowledgetheNSWDepartmentofHealth
studyallcomparisonsinvolvepeoplewhochosetoentertreatment
forprovidingthePHDASdata,andMsPiaSalmelainenofthePhar-
atsomepoint;wedidnotcomparemortalitywithdependentusers
maceuticalServicesBranch,NSWHealth,forherassistancewith
whochoosenottoseektreatment.Wehavemadenoassumptions
dataextractionandinterpretation.
aboutmortalityreductionscomparedtoopioid-dependentpersons
whoneverseektreatment.Third,theelevatedcausesofmortality
AppendixA. Supplementarydata
duringinductionandfollowingcessation,werethosethatopioid
maintenancetreatmentismostlikelytoaffecti.e.thosereflecting
Supplementarydataassociatedwiththisarticlecanbefound,in
therisksofagenerallymorechaoticanddependentillicitdrugusing
theonlineversion,atdoi:10.1016/j.drugalcdep.2009.05.021.
lifestyle,suchasdrugoverdose,accidentsandsuicides.
Itispossiblethattheoutoftreatmentmortalitylevelswedoc-
References
umentedarelowerthantheratesseenpriortotreatmententry,or
amongthosewhoneverentertreatment.Ifthisistrue,thiswould
AustralianBureauofStatistics,2007.2005CausesofDeath,Australia.Canberra,
reducetheobserveddifferencebetweenin-andout-of-treatment
AustralianBureauofStatistics.
mortality, making our assessment of the mortality reduction in Brugal,M.,Domingo-Salvany,A.,Puig,R.,Barrio,G.,deOlalla,P.,delaFuente,L.,2005.
treatmentconservative. Evaluatingtheimpactofmethadonemaintenanceprogrammesonmortality
duetooverdoseandAIDSinacohortofheroinusersinSpain.Addiction100,
981–989.
Burns,L.,Randall,D.,Degenhardt,L.,Hall,W.,Law,M.,Butler,T.,Bell,J.,2009.Opi-
5. Conclusions
oidagonistpharmacotherapyinNewSouthWalesfrom1985to2006:patient
characteristicsandpatternsandpredictorsoftreatmentretention.Addiction,
Mortalityamongopioiddependentpeopleenteringopioidphar- doi:10.1111/j.1360-0443.2009.02633.x.
Buster,M.C.,vanBrussel,G.H.,vandenBrink,W.,2002.Anincreaseinoverdosemor-
macotherapy is elevated compared to age and sex peers, with
talityduringthefirst2weeksafterenteringorre-enteringmethadonetreatment
overdose,externalcausesandsuicidethemajorcontributors.This inAmsterdam.Addiction97,993–1001.
elevatedmortalityishigherwhenoutoftreatment(i.e.treatment Caplehorn,J.R.,1998.DeathsinthefirsttwoweeksofmaintenancetreatmentinNSW
reducesmortality),anditisparticularlyelevatedduringthefirst in1994:identifyingcasesofiatrogenicmethadonetoxicity.DrugandAlcohol
Review17,9–17.
weeksoutoftreatment.Theelevationinmortalityvariedinways Caplehorn,J.R.,Drummer,O.H.,1999.MortalityassociatedwithNewSouthWales
that probably reflect heroin availability and use. Mortality was methadoneprogramsin1994:liveslostandsaved.MedicalJournalofAustralia
highestduringinductionontomethadone.Thisvariedovertime, 170,104–109.
Darke,S.,Degenhardt,L.,Mattick,R.P.(Eds.),2006.MortalityAmongstIllicitDrug
most likely reflecting changing policies on dosing during induc-
Users.CambridgeUniversityPress,Cambridge.
tion.Finally,thisstudyfoundthatmortalitywasequivalentwhether Day,C.,Degenhardt,L.,Hall,W.,2006.DocumentingtheheroinshortageinNew
patientswerereceivingmethadoneorbuprenorphine.Thisfinding SouthWales.DrugandAlcoholReview25,297–305.
Degenhardt,L.,Conroy,E.,Day,C.,Gilmour,S.,Hall,W.,2005.Theimpactofthe
suggeststhatthecomparativelylowermortalityduringinduction
Australianheroinshortageondemandforandcompliancewithtreatmentfor
forbuprenorphinemaybeoffsetbytheincreasedriskofmortality drugdependence.DrugandAlcoholDependence79,129–135.
during more frequent episodes of treatment entry and cessation Degenhardt,L.,Day,C.(Eds.),2004.TheCourseandConsequencesoftheHeroin
ShortageinNewSouthWales.AustralasianCentreforPolicingResearch,Ade-
thatcharacterisebuprenorphineclients.
laide.
Degenhardt,L.,Hall,W.,Lynskey,M.,Warner-Smith,M.,2004.Chapter13Illicitdrug
use.In:Ezzati,M.,Lopez,A.D.,Rodgers,A.,Murray,R.(Eds.),ComparativeQuan-
Roleoffundingsource tificationofHealthRisks:GlobalandRegionalBurdenofDiseaseAttributable
toSelectedMajorRiskFactors,vol.2.WorldHealthOrganization,Geneva,pp.
TheNationalDrugandAlcoholResearchCentreandtheNational 1109–1176.
Degenhardt,L.,Hall,W.,Warner-Smith,M.,2006.Usingcohortstudiestoestimate
CentreinHIVEpidemiologyandClinicalResearcharefundedbythe mortalityamonginjectingdrugusersthatisnotattributabletoAIDS.(review).
AustralianGovernmentDepartmentofHealthandAging,andare SexuallyTransmittedInfections82(Suppl.3),56–63.
bothaffiliatedwiththeFacultyofMedicineattheUniversityofNew Mattick,R.P.,Breen,C.,Kimber,J.,Davoli,M.,2003.Methadonemaintenancether-
apyversusnoopioidreplacementtherapyforopioiddependence.Cochrane
SouthWales.ThisstudyisfundedthroughtheNationalHealthand
DatabaseofSystematicReviews2,CD002209.
MedicalResearchCentreprojectgrant455451.LouisaDegenhardt Mattick,R.P.,Digiusto,E.,Doran,C.,O’Brien,S.,Shanahan,M.,Kimber,J.,Hender-
issupportedbyaNHMRCSeniorResearchFellowship(ID#510279). son,N.,Breen,C.,Shearer,J.,Gates,J.,Shakeshaft,A.,NEPODTrialInvestigators,
2001.Nationalevaluationofpharmacotherapiesforopioddependence(NEPOD).
TonyButlerissupportedbyaNHMRCCareerAward(ID#350992).
Canberra,AustralianGovernmentDepartmentofHealthandAgeing.
NationalCentreinHIVEpidemiologyandClinicalResearch,2007.AustralianNSPsur-
veynationaldatareport2001–2006.Sydney,NewSouthWales,NationalCentre
Contributors inHIVEpidemiologyandClinicalResearch,UniversityofNewSouthWales.
Randall,D.,Roxburgh,A.,Gibson,A.,Degenhardt,L.,2009.MortalityAmongPeople
WhoUseIllicitDrugs:AToolkitforClassifyingMajorCausesofDeath.NDARC
L.Degenhardtconceivedandsupervisedthestudy,andledthe
Technical Report No. 301. National Drug and Alcohol Research Centre, Uni-
writingofthearticle.D.A.Randallundertookthestatisticalanalysis. versityofNSW,Sydney.Downloadablefrom:http://ndarc.med.unsw.edu.au/
W.D.Hallcontributedtothestudydesign.M.Lawprovidedadvice NDARCWeb.nsf/resources/TR+298-302/$file/TR301+Randall+et+al+Classifying+
onthestatisticalanalysisofthestudy.Allauthorscontributedto causes+of+death+2009.pdf.
UnitedNationsOfficeonDrugsandCrime,2008.WorldDrugReport2008.Vienna,
andhaveapprovedthefinalmanuscript. UnitedNations.
L.Degenhardtetal./DrugandAlcoholDependence105 (2009) 9–15 15
Ward,J.,Mattick,R.P.,Hall,W.,1998.MethadoneMaintenanceTreatmentandOther WorldHealthOrganization,1993.ManualoftheInternationalStatisticalClassifica-
OpioidReplacementPharmacotherapies.HarwoodAcademicPublishers,Ams- tionofDiseases,InjuriesandCausesofDeath(tenthedition).Geneva,World
terdam. HealthOrganization.
WorldHealthOrganization,1977.ManualoftheInternationalStatisticalClassifica- WorldHealthOrganization,2005.WHOModelListofEssentialMedicines,14th
tionofDiseases,InjuriesandCausesofDeath(Ninthedition).Geneva,World edition.
HealthOrganization.
